Summit Therapeutics Plc Stock Short Ratio
| SMMT Stock | USD 19.00 0.58 3.15% |
Summit Therapeutics PLC fundamentals help investors to digest information that contributes to Summit Therapeutics' financial success or failures. It also enables traders to predict the movement of Summit Stock. The fundamental analysis module provides a way to measure Summit Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Summit Therapeutics stock.
Summit | Short Ratio |
Summit Therapeutics PLC Company Short Ratio Analysis
Summit Therapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Summit Therapeutics Short Ratio | 5.67 X |
Most of Summit Therapeutics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Summit Therapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Summit Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Summit Therapeutics is extremely important. It helps to project a fair market value of Summit Stock properly, considering its historical fundamentals such as Short Ratio. Since Summit Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Summit Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Summit Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Summit Therapeutics PLC has a Short Ratio of 5.67 times. This is 45.38% higher than that of the Biotechnology sector and 23.48% lower than that of the Health Care industry. The short ratio for all United States stocks is 41.75% lower than that of the firm.
Summit Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Summit Therapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Summit Therapeutics could also be used in its relative valuation, which is a method of valuing Summit Therapeutics by comparing valuation metrics of similar companies.Summit Therapeutics is currently under evaluation in short ratio category among its peers.
Summit Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Summit Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Summit Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Summit Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Summit Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Summit Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Summit Therapeutics' value.| Shares | First Trust Advisors L.p. | 2024-06-30 | 788.1 K | Pictet Asset Manangement Sa | 2024-06-30 | 708.6 K | Td Asset Management Inc | 2024-09-30 | 694.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 674.2 K | Citadel Advisors Llc | 2024-09-30 | 650.8 K | Goldman Sachs Group Inc | 2024-06-30 | 453.9 K | Balyasny Asset Management Llc | 2024-09-30 | 431.2 K | D. E. Shaw & Co Lp | 2024-09-30 | 402.2 K | Barclays Plc | 2024-06-30 | 387.3 K | Baker Bros Advisors Lp | 2024-09-30 | 24.4 M | Vanguard Group Inc | 2024-09-30 | 10.9 M |
Summit Fundamentals
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 13.56 B | ||||
| Shares Outstanding | 737.45 M | ||||
| Shares Owned By Insiders | 84.36 % | ||||
| Shares Owned By Institutions | 11.75 % | ||||
| Number Of Shares Shorted | 17.04 M | ||||
| Price To Earning | 2.85 X | ||||
| Price To Book | 32.00 X | ||||
| Price To Sales | 753.90 X | ||||
| Gross Profit | 705 K | ||||
| EBITDA | 1 M | ||||
| Net Income | (614.93 M) | ||||
| Cash And Equivalents | 121.97 M | ||||
| Cash Per Share | 0.61 X | ||||
| Total Debt | 106.1 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 8.22 X | ||||
| Book Value Per Share | 0.59 X | ||||
| Cash Flow From Operations | (76.76 M) | ||||
| Short Ratio | 5.67 X | ||||
| Earnings Per Share | (0.23) X | ||||
| Target Price | 27.03 | ||||
| Number Of Employees | 105 | ||||
| Beta | -0.92 | ||||
| Market Capitalization | 14.01 B | ||||
| Total Asset | 202.95 M | ||||
| Retained Earnings | (993.26 M) | ||||
| Working Capital | 169.31 M | ||||
| Current Asset | 20.86 M | ||||
| Current Liabilities | 3.21 M | ||||
| Net Asset | 202.95 M |
About Summit Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Summit Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Summit Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Summit Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.